The Clinicians Speak, page-864

I think it probably does mean hospital profit and it strongly affects the choice of treatment in the US compared to say the UK where NICE conducts evaluations on the best value treatments by independent experts. Notably for instance they rejected the "models" provided by Avita for Recell twice saying that th evidence used was repetitive, superficial and weak while US Recell revenues are significantly driven by a minority of "superusers" who apparently take every opportunity to use it even in doubtful circumstances. I would guess that's a choice made based around profit.